References
- Chen J, Ding C, Chen Y, Hu W, Lu Y, Wu W, Zhang Y, Yang B, Wu H, Peng C, et al. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis. J. Oncogenesis. 2020;9(4):42. doi:https://doi.org/10.1038/s41389-020-0226-z
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. J. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:https://doi.org/10.1038/s41575-019-0186-y
- Chava S, Lee C, Aydin Y, Chandra PK, Dash A, Chedid M, Thung SN, Moroz K, Wu T, Nayak NC, et al. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. J. Oncotarget. 2017;8(25):40019–36. doi:https://doi.org/10.18632/oncotarget.16685
- Forner A, Gilabert M, Bruix J, Raoul J-L. Treatment of intermediate-stage hepatocellular carcinoma. J. Nat Rev Clin Oncol. 2014;11(9):525–35. doi:https://doi.org/10.1038/nrclinonc.2014.122
- Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. J. Nat Rev Cancer. 2017;17(5):286–301. doi:https://doi.org/10.1038/nrc.2017.17
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. J. Science. 2015;348(6230):69–74. doi:https://doi.org/10.1126/science.aaa4971
- Pearson RM, Casey LM, Hughes KR, Miller SD, Shea LD. In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. J. Adv Drug Deliv Rev. 2017;114:240–55. (doi:https://doi.org/10.1016/j.addr.2017.04.005
- Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. J. Nature. 2011;480(7378):480–9. doi:https://doi.org/10.1038/nature10673
- Amaravadi RK, Thompson CB. The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment. J. Clin Cancer Res. 2007;13(24):7271–9. doi:https://doi.org/10.1158/1078-0432.CCR-07-1595
- Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. J. Nat Rev Cancer. 2012;12(12):860–75. doi:https://doi.org/10.1038/nrc3380
- Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic Cell Death in Cancer Therapy. J. Annu Rev Immunol. 2013;31(1):51–72. doi:https://doi.org/10.1146/annurev-immunol-032712-100008
- Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol. 1971;105(1):13–20. doi:https://doi.org/10.1002/path.1711050103
- Vandenabeele P, Vandecasteele K, Bachert C, et al. Immunogenic Apoptotic Cell Death and Anticancer Immunity. [M]//GREGORY C D. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy: New Perspectives and Opportunities. Cham; Springer International Publishing. 2016. p. 133–49.
- Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. J. Nat Med. 2007;13(1):54–61. doi:https://doi.org/10.1038/nm1523
- Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini J-L, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. J. Cell Death Differ. 2014;21(1):79–91. doi:https://doi.org/10.1038/cdd.2013.75
- Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. J. Cell Death Differ. 2014;21(1):26–38. doi:https://doi.org/10.1038/cdd.2013.48
- Krysko O, Løve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. J. Cell Death Dis. 2013;4(5):e631-e–e631. doi:https://doi.org/10.1038/cddis.2013.156
- Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. J. Nat Rev Immunol. 2017;17(2):97–111. doi:https://doi.org/10.1038/nri.2016.107
- Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern Recognition Receptors and the Host Cell Death Molecular Machinery. J. Front Immunol. 2018;9:2379. (doi:https://doi.org/10.3389/fimmu.2018.02379
- Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. J. Front Immunol. 2015;6:588 . (doi:https://doi.org/10.3389/fimmu.2015.00588
- Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–701. doi:https://doi.org/10.1084/jem.20050915
- Gao J, Wang W-q, Pei Q, Lord MS, Yu H-j. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):986–94. doi:https://doi.org/10.1038/s41401-020-0400-z
- Galluzzi L, Kepp O, Morselli E, Vitale I, Senovilla L, Pinti M, Zitvogel L, Kroemer G. Viral strategies for the evasion of immunogenic cell death. J Intern Med. 2010;267(5):526–42. doi:https://doi.org/10.1111/j.1365-2796.2010.02223.x
- Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014; 3(9):e955691–e. doi:https://doi.org/10.4161/21624011.2014.955691
- Wang Y, Han X, Li YD, et al. Effects of tumor-specific antigen induced by lentinan on murine H22 hepatocellular carcinoma immunoprophylaxis. Eur Rev Med Pharmacol Sci. 2015; 19(23):4516–24.
- Allen-Worthington KH, Brice AK, Marx JO, Hankenson FC. Intraperitoneal Injection of Ethanol for the Euthanasia of Laboratory Mice (Mus musculus) and Rats (Rattus norvegicus). Am Assoc Lab Anim Sci. 2015;54(6):769–78.
- Zhang M, Zhang Y, Zhang L, et al. Chapter Thirteen - Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China [M]//ZHANG L. Progress in Molecular Biology and Translational Science. Cambridge, MA: Academic Press. 2019. p. 297–328.
- Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. J. Cell. 2017;168(4):670–91. doi:https://doi.org/10.1016/j.cell.2016.11.037
- Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites. J. Nat Rev Cancer. 2002;2(8):563–72. doi:https://doi.org/10.1038/nrc865
- Collin M. Immune checkpoint inhibitors: a patent review (2010-2015). J. Expert Opin Ther Pat. 2016;26(5):555–64. doi:https://doi.org/10.1080/13543776.2016.1176150
- Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P. Recent advances in understanding the complexities of metastasis. F1000Res. 2018;7:1169. (F1000 Faculty Rev-169. doi:https://doi.org/10.12688/f1000research.15064.1
- Asadzadeh Z, Safarzadeh E, Safaei S, Baradaran A, Mohammadi A, Hajiasgharzadeh K, Derakhshani A, Argentiero A, Silvestris N, Baradaran B, et al. Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers (Basel. 2020;12(4):1047. doi:https://doi.org/10.3390/cancers12041047
- Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008;14(4):141–51. doi:https://doi.org/10.1016/j.molmed.2008.02.002
- Zhang Y, Zheng Z, Yang X, Pan X, Yin L, Huang X, Li Q, Shu Y, Zhang Q, Wang K, et al. A sensitive and rapid radiolabelling method for the in vivo pharmacokinetic study of lentinan. Food Funct. 2018;9(6):3114–25. doi:https://doi.org/10.1039/C8FO00272J
- Chen H-M, Wang P-H, Chen S-S, Wen C-C, Chen Y-H, Yang W-C, Yang N-S. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. J. Cancer Immunol Immunother. 2012;61(11):1989–2002. doi:https://doi.org/10.1007/s00262-012-1258-9
- Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. J. Oncogene. 2011;30(10):1147–58. doi:https://doi.org/10.1038/onc.2010.500
- Adkins I, Fucikova J, Garg AD, Agostinis P, Špíšek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014;3(12):e968434. doi:https://doi.org/10.4161/21624011.2014.968434
- Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. J. Cytokine Growth Factor Rev. 2013;24(4):319–33. doi:https://doi.org/10.1016/j.cytogfr.2013.01.005
- Wang Y-J, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. J. Genes Dis. 2018;5(3):194–203. doi:https://doi.org/10.1016/j.gendis.2018.05.003
- Matzinger P. Tolerance, danger, and the extended family. J. Annu Rev Immunol. 1994;12:991–1045. doi:https://doi.org/10.1146/annurev.iy.12.040194.005015
- Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. J. Oncogene. 2016;35(46):5931–41. doi:https://doi.org/10.1038/onc.2016.104